Literature DB >> 18370491

Encapsulation of commercially available losartan for blinding purposes does not affect its bioavailability.

L Nyman1, K Taure, M Cullberg, P O Lagerström.   

Abstract

Entities:  

Year:  1998        PMID： 18370491     DOI： 10.2165/00044011-199815040-00012

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  3 in total

1.  The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan.

Authors:  O K Andersson; S Neldam
Journal:  Blood Press       Date:  1998-01       Impact factor: 2.835

Review 2.  Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension.

Authors:  K L Goa; A J Wagstaff
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

3.  Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans.

Authors:  M W Lo; M R Goldberg; J B McCrea; H Lu; C I Furtek; T D Bjornsson
Journal:  Clin Pharmacol Ther       Date:  1995-12       Impact factor: 6.875
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.